scispace - formally typeset
S

Setsuro Fujii

Researcher at Osaka University

Publications -  150
Citations -  3272

Setsuro Fujii is an academic researcher from Osaka University. The author has contributed to research in topics: Kallikrein & Plasmin. The author has an hindex of 24, co-authored 150 publications receiving 3214 citations. Previous affiliations of Setsuro Fujii include University of Tokushima & Otsuka Pharmaceutical.

Papers
More filters
Journal ArticleDOI

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species.

TL;DR: CS-514 markedly reduced serum cholesterol levels in dogs, monkeys and rabbits, including Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia in man, but did not reduce those in rats and mice.
Journal ArticleDOI

New synthetic inhibitors of C1r̄, C1 esterase, thrombin, plasmin, kallikrein and trypsin

TL;DR: 6'-amidino-2-naphthyl-4-guanidinobenzoate dihydrochloride, 4-(beta- amidinoethenyl)phenyl- 4-guAnidin Obenzoates dimethanesulfonate and 4-amidinos2-benzoylphenyl the most effective inhibitors of trypsin, plasmin, pancreatic kallikrein and thrombin.
Journal ArticleDOI

Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.

TL;DR: It was found that the antitumor activity of FT-207 on sarcoma-180 and AH-130 tumor was enhanced by oral administration of uracil, dUrd, or Urd, and this enhancement of the antitumsor activity increased with the dose of Uracil.
Journal ArticleDOI

Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase.

TL;DR: These derivatives were the most effective inhibitors of trypsin, plasmin, plasma kallikrien and thrombin, and they strongly inhibited the esterolytic activities of C1r- and C1 esterase.
Journal ArticleDOI

Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents

TL;DR: Results suggest that at the clinical doses the optimum molar ratio of uracil to FT-207 is 4.5:1, and cytosine enhanced the antitumor activity ofFT-207 on sarcoma-180 in mice, but its coadministration resulted in a lower concentration of 5-FU in the tumor than co administration of urACil.